The remarkable promise of a single infusion to potentially cure life-limiting diseases has made gene therapy one of the outstanding developments in biopharma in recent years - and big companies have already bought up several pioneers in the field.
The most notable of these was Novartis AG's acquisition of AveXis in April 2018 for $8.7bn, a move which...






